RCEL

AVITA Medical, Inc. [RCEL] Stock Forecast

Q: What is AVITA Medical, Inc. stock symbol ?

AVITA Medical, Inc. is a US stock, located in Valencia of Ca and trading under the symbol RCEL

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

RCEL Stock Summary

Earnings have grown 17.75% per last year.

Earnings are expected to rise 50.19% next year

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been decreasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

RCEL has less than 1 year of cash runway

Top 10 Correlated ETFs

RCEL

Top 10 Correlated Stocks

RCEL

In the News

04:30 29 Sep 2023 RCEL

AVITA Medical to Present at the Cantor Global Healthcare Conference

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time.

06:45 29 Sep 2023 RCEL

AVITA Medical to Participate in Upcoming Investor Conferences

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management team will participate in the following upcoming investor conferences:

10:47 29 Sep 2023 RCEL

AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Brooks O'Neil - Lake Street Capital Markets Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Ross Osborne - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. Second Quarter 2023 Earnings Call.

08:54 29 Sep 2023 RCEL

AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair

AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force positioned to capitalize.

08:08 29 Sep 2023 RCEL

Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?

Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

02:25 29 Sep 2023 RCEL

Why Shares of Avita Medical Are Soaring Thursday

Avita specializes in devices and therapies to restore skin growth. The FDA's nod means that the company's Recell system can expand beyond applications for burn patients.

12:23 29 Sep 2023 RCEL

AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System

AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.

10:08 29 Sep 2023 RCEL

AVITA Medical, Inc. (RCEL) Q1 2023 Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Phillip Dantoin - Piper Sandler Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2023 Earnings Conference Call.

09:55 29 Sep 2023 RCEL

Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

04:30 29 Sep 2023 RCEL

AVITA Medical to Announce First Quarter 2023 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, April 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 11, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 12, 2023, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.

RCEL Financial details

Company Rating

Neutral

Market Cap

355.93M

Income

-30.55M

Revenue

40.85M

Book val./share

2.72

Cash/share

2.62

Dividend

Dividend %

Employees

126

Optionable

Shortable

Yes

Earnings

08 Nov 2023

P/E

-12.05

Forward P/E

PEG

-20.14

P/S

9.09

P/B

5.36

P/C

5.58

P/FCF

-14.74

Quick Ratio

5.23

Current Ratio

5.61

Debt / Equity

0.02

LT Debt / Equity

0.02

EPS (TTM)

-1.24

EPS next Y

EPS next Q

-0.63

EPS this Y

-8.55%

EPS next Y

EPS next 5Y

63.31%

EPS last 5Y

-3.82%

Revenue last 5Y

95.23%

Revenue Q/Q

11.4%

EPS Q/Q

10.81%

SMA20

-12.5%

SMA50

-26.32%

SMA100

-12.5%

Inst Own

30.23%

Inst Trans

1.33%

ROA

-35%

ROE

-38%

ROC

-0.45%

Gross Margin

83%

Oper. Margin

-80%

Profit Margin

-75%

Payout

Shs Outstand

25.48M

Shs Float

116.16M

Target Price

52W Range

4.41-21.7

52W High

-30.33%

52W Low

+265.75%

RSI

Rel Volume

0.23

Avg Volume

229.99K

Volume

52.09K

Perf Week

5.56%

Perf Month

-7.64%

Perf Quarter

-8.05%

Perf Half Y

8.13%

Beta

1.25113

Volatility

0.32%, 0.89%

Prev Close

0.34%

Price

14.63

Change

1.39%

RCEL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-06-30	2020-06-30	2021-06-30	2021-06-30	2022-12-31
Revenue per share	0.13	0.34	0.7	1.29	1.38
Net income per share	-1.3	-1.53	-2.07	-1.17	-1.07
Operating cash flow per share	-1.29	-1.2	-1.12	-1.14	-0.76
Free cash flow per share	-1.33	-1.25	-1.16	-1.19	-0.78
Cash per share	1.17	1.26	3.63	4.88	3.17
Book value per share	1.5	1.3	3.57	5.1	3.39
Tangible book value per share	1.5	1.28	3.55	5.08	3.37
Share holders equity per share	1.5	1.3	3.57	5.1	3.39
Interest debt per share	0.01	0	0.1	0.04	0.04
Market cap	68.01M	709.12M	416.37M	465.28M	165M
Enterprise value	57.22M	688.86M	344.65M	355.41M	147.76M
P/E ratio	-5.62	-28.8	-9.91	-17.5	-6.19
Price to sales ratio	56.04	131.41	29.19	15.92	4.79
POCF ratio	-5.66	-36.84	-18.3	-17.96	-8.64
PFCF ratio	-5.49	-35.29	-17.65	-17.18	-8.41
P/B Ratio	4.86	33.99	5.75	4.02	1.95
PTB ratio	4.86	33.99	5.75	4.02	1.95
EV to sales	47.15	127.65	24.16	12.16	4.29
Enterprise value over EBITDA	-4.36	-27.86	-8.3	-13.4	-5.67
EV to operating cash flow	-4.76	-35.79	-15.15	-13.72	-7.74
EV to free cash flow	-4.62	-34.28	-14.61	-13.13	-7.53
Earnings yield	-0.18	-0.03	-0.1	-0.06	-0.16
Free cash flow yield	-0.18	-0.03	-0.06	-0.06	-0.12
Debt to equity	0.01	0	0.03	0.01	0.01
Debt to assets	0.01	0	0.02	0.01	0.01
Net debt to EBITDA	0.82	0.82	1.73	4.14	0.66
Current ratio	5.75	5.5	10.17	16.42	8.18
Interest coverage	-672.47	-934.69	-1.29K	-1.21K	-1.72K
Income quality	0.99	0.78	0.54	0.97	0.72
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	6.63	2.35	2.43	0.77	0.68
Research and developement to revenue	5.24	1.86	0.59	0.51	0.4
Intangibles to total assets	0	0.01	0	0	0
Capex to operating cash flow	0.03	0.04	0.04	0.05	0.03
Capex to revenue	-0.3	-0.16	-0.06	-0.04	-0.02
Capex to depreciation	-3.47	-3.2	-1.82	-1.64	-0.92
Stock based compensation to revenue	0	0.36	1.16	0.19	0.2
Graham number	6.62	6.69	12.9	11.6	9.02
ROIC	-0.85	-1.17	-0.56	-0.23	-0.32
Return on tangible assets	-0.72	-0.97	-0.51	-0.21	-0.27
Graham Net	1.22	1.08	3.25	4.73	2.82
Working capital	13.54M	19.82M	70.68M	113.94M	76.77M
Tangible asset value	13.98M	20.64M	72.04M	115.18M	84.28M
Net current asset value	13.44M	19.35M	68.33M	111.48M	73.93M
Invested capital	0.01	0	0.03	0.01	0.01
Average receivables	2.81M	3.05M	2.26M	4.92M	6.18M
Average payables	2.19M	3.25M	4.14M	3.73M	3.06M
Average inventory	823.16K	794.93K	932.9K	1.39M	1.89M
Days sales outstanding	1.21K	141.17	62.24	92.44	52.6
Days payables outstanding	1.81K	1.21K	531.97	191.43	181.38
Days of inventory on hand	598.43	227.4	138.12	101.05	128.39
Receivables turnover	0.3	2.59	5.86	3.95	6.94
Payables turnover	0.2	0.3	0.69	1.91	2.01
Inventory turnover	0.61	1.61	2.64	3.61	2.84
ROE	-0.87	-1.18	-0.58	-0.23	-0.31
Capex per share	-0.04	-0.05	-0.04	-0.05	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0.33	0.36	0.42	0.42	0.47
Net income per share	-0.25	-0.22	-0.24	-0.37	-0.41
Operating cash flow per share	-0.14	-0.11	-0.15	-0.36	-0.36
Free cash flow per share	-0.15	-0.12	-0.16	-0.37	-0.37
Cash per share	3.38	3.37	3.5	2.91	2.62
Book value per share	3.71	3.52	3.74	3.08	2.72
Tangible book value per share	3.69	3.5	3.72	3.06	2.7
Share holders equity per share	3.71	3.52	3.74	3.08	2.72
Interest debt per share	0.02	0.04	0.04	0.07	0.07
Market cap	118.61M	131.79M	149.65M	352.07M	429.33M
Enterprise value	84.41M	109.29M	132.4M	325.9M	392.89M
P/E ratio	-4.74	-5.9	-6.99	-9.55	-10.34
Price to sales ratio	14.23	14.49	15.83	33.37	36.53
POCF ratio	-33.82	-47.46	-43.55	-38.8	-47.17
PFCF ratio	-31.71	-45.41	-42.44	-37.56	-45.65
P/B Ratio	1.28	1.5	1.77	4.54	6.25
PTB ratio	1.28	1.5	1.77	4.54	6.25
EV to sales	10.13	12.02	14	30.89	33.43
Enterprise value over EBITDA	-13.8	-20.09	-25.5	-36.01	-37.91
EV to operating cash flow	-24.07	-39.36	-38.53	-35.92	-43.17
EV to free cash flow	-22.56	-37.66	-37.55	-34.77	-41.77
Earnings yield	-0.05	-0.04	-0.04	-0.03	-0.02
Free cash flow yield	-0.03	-0.02	-0.02	-0.03	-0.02
Debt to equity	0.01	0.01	0.01	0.02	0.02
Debt to assets	0.01	0.01	0.01	0.02	0.02
Net debt to EBITDA	5.59	4.13	3.32	2.89	3.52
Current ratio	11.64	9.64	8.18	7.21	5.61
Interest coverage	-1.59K	-958	-984.67	-2.48K	-1.6K
Income quality	0.56	0.5	0.64	0.98	0.88
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.66	0.55	0.56	0.79	0.52
Research and developement to revenue	0.37	0.42	0.36	0.43	0.43
Intangibles to total assets	0	0	0	0	0.01
Capex to operating cash flow	0.07	0.05	0.03	0.03	0.03
Capex to revenue	-0.03	-0.01	-0.01	-0.03	-0.03
Capex to depreciation	-1.71	-0.91	-0.69	-2.23	-2.08
Stock based compensation to revenue	0.17	0.16	0.13	0.25	0.1
Graham number	4.57	4.21	4.46	5.03	5.02
ROIC	-0.07	-0.06	-0.07	-0.12	-0.16
Return on tangible assets	-0.06	-0.06	-0.05	-0.1	-0.12
Graham Net	3.15	3.06	3.11	2.53	2.16
Working capital	83.92M	82.21M	76.77M	71.28M	63.69M
Tangible asset value	92.13M	87.54M	84.28M	77.1M	68.19M
Net current asset value	81.7M	79.77M	73.93M	67.7M	59.81M
Invested capital	0.01	0.01	0.01	0.02	0.02
Average receivables	4.28M	4.45M	4.73M	5.07M	5.69M
Average payables	2.45M	3.05M	3.3M	3.38M	3.79M
Average inventory	1.91M	1.99M	2.04M	2.47M	2.93M
Days sales outstanding	47.37	44.62	47.21	44.2	47.45
Days payables outstanding	162.01	211.65	200.58	202.57	156.68
Days of inventory on hand	131.3	115.29	141.98	151.76	124.87
Receivables turnover	1.9	2.02	1.91	2.04	1.9
Payables turnover	0.56	0.43	0.45	0.44	0.57
Inventory turnover	0.69	0.78	0.63	0.59	0.72
ROE	-0.07	-0.06	-0.06	-0.12	-0.15
Capex per share	-0.01	0	0	-0.01	-0.01

RCEL Frequently Asked Questions

What is AVITA Medical, Inc. stock symbol ?

AVITA Medical, Inc. is a US stock , located in Valencia of Ca and trading under the symbol RCEL

What is AVITA Medical, Inc. stock quote today ?

AVITA Medical, Inc. stock price is $14.63 today.

Is AVITA Medical, Inc. stock public?

Yes, AVITA Medical, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 229.99K
Market Capitalization 355.93M
Employee 126
CEO Mr. James M. Corbett
Headquarters Valencia,CA,US
IPO Date 2012-05-14
Website https://www.avitamedical.com

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.